<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15877">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900196</url>
  </required_header>
  <id_info>
    <org_study_id>NU372</org_study_id>
    <nct_id>NCT02900196</nct_id>
  </id_info>
  <brief_title>Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danone Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danone Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to evaluate the effect of a four-week consumption of a
      fresh fermented dairy drink containing probiotic strains on Antibiotic-Associated Diarrhea
      and Gastro-Intestinal disorders in adult subjects treated for Helicobacter pylori
      eradication.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of AAD</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of AAD</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event of AAD</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Clostridium difficile Associated Diarrhea</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event of Clostridium difficile Associated Diarrhea</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Clostridium difficile Associated Diarrhea</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with main GI symptoms (diarrhea, abdominal pain, bloating, nausea, vomiting)</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of gastrointestinal symptoms</measure>
    <time_frame>From Day 0 to Day 28</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Clostridium difficile analysis in feces</measure>
    <time_frame>from Day 0 to Day 28</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Microbiota analysis in feces</measure>
    <time_frame>from Day 0 to Day 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Short-Chain Fatty Acids analysis in blood and feces</measure>
    <time_frame>from Day 0 to Day 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Calprotectin analysis in feces</measure>
    <time_frame>from Day 0 to Day 42</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Microbiological assessment of probiotic bacterial strains (of study product) in subjects feces</measure>
    <time_frame>from Day 0 to Day 42</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">295</enrollment>
  <condition>Antibiotic-Associated Diarrhea</condition>
  <arm_group>
    <arm_group_label>1 - Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2 - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1 - Fermented dairy drink</intervention_name>
    <description>1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)</description>
    <arm_group_label>1 - Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 - Acidified dairy drink</intervention_name>
    <description>2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)</description>
    <arm_group_label>2 - Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have read and signed the Study Informed Consent Form

          -  Subjects positive for Helicobacter pylori infection and symptomatic due to
             Helicobacter pylori infection

          -  Subjects with an indication, as stated by a Gastroenterologist, for the eradication
             of Helicobacter pylori

        Exclusion Criteria:

          -  Female subjects with a positive pregnancy test (based on serum test), or planning to
             become pregnant during the study or breast-feeding women

          -  Subjects enrolled in another interventional clinical study in the last 4 weeks or in
             an exclusion period following participation in another clinical trial

          -  Subject who have a history of alcohol abuse

          -  Subjects having diarrhea within the preceding 4-weeks

          -  Subjects with severe life-threatening illness, severe evolutive or chronic pathology

          -  Immune-suppressed subjects

          -  Subjects with benign peptic ulcer or pre-malignant or malignant lesion

          -  Subjects presenting with an infection of the gastrointestinal tract

          -  Subjects with any past severe gastro-intestinal or metabolic pathology

          -  Subjects with history of Helicobacter pylori eradication therapy

          -  Subjects with history of cardiac or renal clinically significant disease

          -  Subjects that have had any surgery or intervention requiring general anesthesia in
             the last 4 weeks, or that have any planned

          -  Subjects with allergy or hypersensitivity against the medication for the eradication
             of Helicobacter pylori

          -  Subjects taking treatments likely to interfere with the evaluation of study
             parameters.

          -  Subjects with allergy or hypersensitivity to any component of the study products
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Guillemard, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Danone Research, Palaiseau, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florent Schäfer</last_name>
    <phone>+33 (0) 1 69 35 74 31</phone>
    <email>florent.schafer@danone.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-François Jeanne</last_name>
    <email>jean-francois.jeanne@danone.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité Research Organisation GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Wagner, MD, PhD</last_name>
      <phone>+49 30 450 539 200</phone>
      <email>enquiries@charite-research.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <lastchanged_date>September 19, 2016</lastchanged_date>
  <firstreceived_date>September 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Probiotics</keyword>
  <keyword>Antibiotic Associated Diarrhea</keyword>
  <keyword>Gastro-Intestinal disorders</keyword>
  <keyword>Helicobacter pylori</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
